Topics:

SoloPak Obtains Rights to Ganite

SoloPak Obtains Rights to Ganite

ELK GROVE VILLAGE, Ill--SoloPak Pharmaceuticals, Inc. has signed an agreement with Sloan-Kettering Institute for Cancer Research to acquire the exclusive worldwide rights to gallium nitrate (Ganite), which was FDA approved in 1991 for the treatment of acute hypercalcemia in cancer patients and had been manufactured by Fujisawa USA (Deerfield, Ill).

The agreement involves a grant of SoloPak equity to the Institute and a commitment of funds from SoloPak to complete clinical trials.

Over the next 2 to 3 years, SoloPak plans to seek approval of gallium nitrate for the treatment of chronic hypercalcemia and bone metastases in cancer patients, and to launch clinical trials of the agent in Paget's disease and osteoporosis.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.